[HTML][HTML] Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non–small cell lung cancer …
DR Spigel, M McCleod, RM Jotte, L Einhorn… - Journal of Thoracic …, 2019 - Elsevier
Abstract Introduction CheckMate 153 (NCT02066636) is a phase 3B/4 study assessing
nivolumab in previously treated patients with advanced NSCLC. Eligibility criteria allowed …
nivolumab in previously treated patients with advanced NSCLC. Eligibility criteria allowed …
[HTML][HTML] Multiplex detection of rare mutations by picoliter droplet based digital PCR: sensitivity and specificity considerations
E Zonta, F Garlan, N Pécuchet, K Perez-Toralla… - PloS one, 2016 - journals.plos.org
In cancer research, the accuracy of the technology used for biomarkers detection is
remarkably important. In this context, digital PCR represents a highly sensitive and …
remarkably important. In this context, digital PCR represents a highly sensitive and …
miRNA-19 promotes non-small-cell lung cancer cell proliferation via inhibiting CBX7 expression
X Peng, L Guan, B Gao - OncoTargets and therapy, 2018 - Taylor & Francis
Background miR-19 is a critical carcinogenic miRNA that participates in important biological
processes of human malignancies. CBX7 plays a key role in lung cancer development and …
processes of human malignancies. CBX7 plays a key role in lung cancer development and …
[HTML][HTML] Real-world treatment patterns and outcomes of patients with metastatic nonsquamous non-small cell lung cancer after progression on standard-of-care …
HA Divan, MA Bittoni, A Krishna, DP Carbone - Lung Cancer, 2023 - Elsevier
Objectives Data to guide treatment selection in metastatic nonsquamous (mNSq) non-small
cell lung cancer (NSCLC) after progression on current standard-of-care (SoC) treatment are …
cell lung cancer (NSCLC) after progression on current standard-of-care (SoC) treatment are …
[HTML][HTML] Discovery of novel biomarkers of therapeutic responses in Han Chinese pemetrexed-based treated advanced NSCLC patients
X Zhang, D Zhang, L Huang, G Li, L Chen… - Frontiers in …, 2019 - frontiersin.org
Pemetrexed, one of the most commonly used drugs in advanced non–small cell lung cancer
(NSCLC) therapies, often leads to various therapeutic responses in patients. These …
(NSCLC) therapies, often leads to various therapeutic responses in patients. These …
Clinical Features of EGFR Mutation Negative in Patients with Non-small Cell Lung Cancer and Brain Metastases.
ZHU Yixiang, Y Zhang - Chinese Journal of Lung Cancer, 2021 - search.ebscohost.com
In addition to rare incidence of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1
receptor kinase (ROS1) positive patients, patients with brain metastases of non-small cell …
receptor kinase (ROS1) positive patients, patients with brain metastases of non-small cell …
Efficacy and safety of apatinib plus vinorelbine in patients with wild-type advanced non–small cell lung cancer after second-line treatment failure: a nonrandomized …
X Zhang, Y Xiong, Q Xia, F Wu, L Liu, Y Zhou… - JAMA Network …, 2020 - jamanetwork.com
Importance There is currently no standard treatment strategy for patients with advanced non–
small cell lung cancer (NSCLC) without driver gene variation after failure of 2 or more lines …
small cell lung cancer (NSCLC) without driver gene variation after failure of 2 or more lines …
Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan
H Isobe, K Mori, K Minato, H Katsura… - Lung Cancer: Targets …, 2017 - Taylor & Francis
Background Recommended therapies for advanced/metastatic non-small cell lung cancer
(NSCLC) have changed with the advent of targeted therapies. The objectives of this …
(NSCLC) have changed with the advent of targeted therapies. The objectives of this …
[HTML][HTML] EGFR 敏感突变阴性非小细胞肺癌脑转移患者临床特征
朱以香， 张烨 - Chinese Journal of Lung Cancer, 2021 - ncbi.nlm.nih.gov
除少见的间变性淋巴瘤激酶（ anaplastic lymphoma kinase, ALK） 及原癌基因-1
受体酪氨酸激酶（ c-ros oncogene 1-receptor tyrosine kinase, ROS1） 阳性敏感融合外 …
受体酪氨酸激酶（ c-ros oncogene 1-receptor tyrosine kinase, ROS1） 阳性敏感融合外 …
Quantitative and qualitative assessment of real world data comparative effectiveness research of systemic therapies in lung oncology: a systematic review
BJM Peters, VEMT Janssen, FM Schramel… - Cancer …, 2016 - Elsevier
Introduction The growing interest in comparative effectiveness research (CER) based on
data from routine clinical practice also extends towards lung oncology. Although CER …
data from routine clinical practice also extends towards lung oncology. Although CER …